Neurocrine Biosciences, Inc. (LON:0K6R)
London · Delayed Price · Currency is GBP · Price in USD 137.64
-10.63 (-7.17%)
At close: Oct 29, 2025
Neurocrine Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Cash & Equivalents | 340.2 | 233 | 251.1 | 262.9 | 340.8 | 187.1 | Upgrade |
Short-Term Investments | 774.6 | 843.1 | 780.5 | 726.4 | 370.5 | 613.9 | Upgrade |
Cash & Short-Term Investments | 1,115 | 1,076 | 1,032 | 989.3 | 711.3 | 801 | Upgrade |
Cash Growth | -9.22% | 4.31% | 4.28% | 39.08% | -11.20% | 19.46% | Upgrade |
Receivables | 728 | 479.1 | 439.3 | 350 | 185.5 | 157.1 | Upgrade |
Inventory | 69.3 | 57.4 | 38.3 | 35.1 | 30.5 | 28 | Upgrade |
Other Current Assets | 68.2 | 112.1 | 97.8 | 79.1 | 45.5 | 30.1 | Upgrade |
Total Current Assets | 2,158 | 1,725 | 1,607 | 1,454 | 972.8 | 1,016 | Upgrade |
Property, Plant & Equipment | 566.2 | 592 | 347.3 | 145.6 | 155.8 | 127.4 | Upgrade |
Long-Term Investments | 1,117 | 864.3 | 849.4 | 401.5 | 624.4 | 265.3 | Upgrade |
Goodwill | - | 5.7 | 5.8 | 5.4 | - | - | Upgrade |
Other Intangible Assets | 35.7 | 36.5 | 35.5 | 37.2 | - | - | Upgrade |
Long-Term Deferred Tax Assets | 368.5 | 485.7 | 362.6 | 305.9 | 315.1 | 319.4 | Upgrade |
Other Long-Term Assets | 20.3 | 9.8 | 43.8 | 19.6 | 4.4 | 6.4 | Upgrade |
Total Assets | 4,266 | 3,719 | 3,251 | 2,369 | 2,073 | 1,735 | Upgrade |
Accounts Payable | 119.9 | 110 | 133.3 | 67.3 | 51.5 | 39.4 | Upgrade |
Accrued Expenses | 464.4 | 351.6 | 315.5 | 271.3 | 111.6 | 94.7 | Upgrade |
Current Portion of Long-Term Debt | - | - | 170.1 | 169.4 | - | - | Upgrade |
Current Portion of Leases | 51.3 | 40.6 | - | - | - | - | Upgrade |
Current Income Taxes Payable | - | - | - | 9 | - | - | Upgrade |
Current Unearned Revenue | - | - | - | - | 62.7 | 34.6 | Upgrade |
Other Current Liabilities | 2.4 | 5.5 | 35.9 | 20.7 | 20 | 17.8 | Upgrade |
Total Current Liabilities | 638 | 507.7 | 654.8 | 537.7 | 245.8 | 186.5 | Upgrade |
Long-Term Debt | - | - | - | - | 335.1 | 317.9 | Upgrade |
Long-Term Leases | 428.4 | 455.1 | 258.3 | 93.5 | 105.3 | 94.4 | Upgrade |
Other Long-Term Liabilities | 195.7 | 166.2 | 106.3 | 29.7 | 12.3 | 9.7 | Upgrade |
Total Liabilities | 1,262 | 1,129 | 1,019 | 660.9 | 698.5 | 608.5 | Upgrade |
Common Stock | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | Upgrade |
Additional Paid-In Capital | 2,696 | 2,555 | 2,382 | 2,122 | 2,011 | 1,850 | Upgrade |
Retained Earnings | 294 | 29.2 | -157.1 | -406.8 | -635.8 | -725.4 | Upgrade |
Comprehensive Income & Other | 13.2 | 5.8 | 7 | -7.9 | -1.7 | 1.8 | Upgrade |
Shareholders' Equity | 3,004 | 2,590 | 2,232 | 1,708 | 1,374 | 1,126 | Upgrade |
Total Liabilities & Equity | 4,266 | 3,719 | 3,251 | 2,369 | 2,073 | 1,735 | Upgrade |
Total Debt | 479.7 | 495.7 | 428.4 | 262.9 | 440.4 | 412.3 | Upgrade |
Net Cash (Debt) | 635.1 | 580.4 | 603.2 | 726.4 | 270.9 | 388.7 | Upgrade |
Net Cash Growth | -32.56% | -3.78% | -16.96% | 168.14% | -30.31% | 122.11% | Upgrade |
Net Cash Per Share | 6.21 | 5.60 | 5.97 | 7.34 | 2.77 | 3.97 | Upgrade |
Filing Date Shares Outstanding | 99.71 | 99.7 | 99.51 | 96.59 | 95.24 | 93.94 | Upgrade |
Total Common Shares Outstanding | 99.7 | 99.4 | 98.7 | 96.5 | 94.9 | 93.5 | Upgrade |
Working Capital | 1,520 | 1,217 | 952.2 | 915.8 | 727 | 829.7 | Upgrade |
Book Value Per Share | 30.13 | 26.05 | 22.61 | 17.70 | 14.48 | 12.04 | Upgrade |
Tangible Book Value | 2,968 | 2,548 | 2,191 | 1,665 | 1,374 | 1,126 | Upgrade |
Tangible Book Value Per Share | 29.77 | 25.63 | 22.20 | 17.26 | 14.48 | 12.04 | Upgrade |
Machinery | - | 153.2 | 115.7 | 87 | 75.6 | 56.8 | Upgrade |
Leasehold Improvements | - | 35.9 | 38.1 | 37.9 | 34.9 | 29.5 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.